Demyelination is the destruction or loss of myelin, the protective insulating layer that wraps around nerve fibers throughout your body. When this coating is damaged, nerve signals slow down or stop entirely, causing symptoms that range from numbness and tingling to vision loss and difficulty walking. The most well-known demyelinating condition is multiple sclerosis (MS), but several other diseases can strip myelin from nerves in both the brain and the rest of the body.
What Myelin Does and Why It Matters
Myelin is a fatty membrane wrapped around nerve fibers in a tight spiral, much like insulation around an electrical wire. In the brain and spinal cord (the central nervous system), cells called oligodendrocytes produce myelin. In the nerves of your arms, legs, and organs (the peripheral nervous system), cells called Schwann cells do the same job.
The myelin sheath isn’t continuous. It has small gaps spaced roughly a millimeter apart called nodes of Ranvier. These gaps are the only spots where the nerve fiber is exposed and where sodium channels sit. When a nerve fires, the electrical signal can’t pass through the insulated, myelin-covered sections, so it jumps from one gap to the next. This jumping process, called saltatory conduction, makes signal transmission dramatically faster than it would be in an uninsulated nerve. It also requires far less energy, because only the tiny exposed patches of the nerve need to generate an electrical charge rather than the entire length of the fiber.
This is why losing myelin has such widespread effects. Without that insulation, signals either crawl along the nerve or fail to arrive at all.
What Happens During Demyelination
Demyelination destroys the myelin-producing cells, the myelin layers themselves, or both, while initially leaving the underlying nerve fiber (the axon) relatively intact. The distinction matters: as long as the axon survives, there is at least some potential for repair. But in many demyelinating diseases, particularly MS, the damage doesn’t stop at myelin. Lesion sites often show both clear myelin loss and direct injury to the axons underneath. Dying oligodendrocytes have been observed at considerable distances from the original injury site, which means the damage can spread beyond where it first appears.
Once myelin is gone from a section of nerve, impulse conduction through that stretch is either blocked completely or significantly slowed. Which neurological symptoms you experience depends entirely on where in the nervous system the damage occurs.
Common Causes of Demyelination
The most common cause is an autoimmune attack, where the immune system mistakenly targets myelin or the cells that produce it. In MS, this attack causes inflammation and swelling that injures the myelin sheath and, over time, the nerve fibers it protects. Other autoimmune demyelinating conditions include Guillain-Barré syndrome (which targets peripheral nerves), neuromyelitis optica (which primarily affects the optic nerves and spinal cord), and acute disseminated encephalomyelitis, which can follow a viral infection.
Demyelination can also result from non-autoimmune causes: certain viral infections, exposure to toxins, severe nutritional deficiencies (particularly vitamin B12), and rare inherited conditions that prevent the body from forming or maintaining normal myelin.
The distinction between central and peripheral demyelination is clinically important. Central demyelination, affecting the brain and spinal cord, involves damage to oligodendrocytes. Peripheral demyelination involves Schwann cells in the nerves outside the brain and spine. The symptoms, diagnostic approach, and treatment differ significantly between the two.
Symptoms of Demyelination
Symptoms depend on which nerves are affected, but some patterns are common enough to be recognizable.
Sensory symptoms are the most frequent first sign in MS, appearing as the initial complaint in 21% to 55% of patients and eventually developing in nearly all of them. These include numbness, tingling, burning sensations, and heightened sensitivity to touch. A typical pattern starts with numbness or tingling in one foot, then climbs up that leg, crosses to the other side, and may continue up the trunk or into the arms. Poor balance, weakness, urinary urgency, and constipation often accompany these sensory changes.
Vision problems are another hallmark. Optic neuritis, inflammation of the nerve connecting the eye to the brain, is the first symptom in 14% to 23% of MS patients. More than half will experience it at some point. It typically causes vision loss in one eye that worsens over a few days, often accompanied by pain around the eye that gets worse with movement. Colors may look washed out, and there may be a blind spot in the center of vision.
Coordination problems develop when demyelination affects the pathways running through the cerebellum. This can cause unsteady walking, difficulty with fine movements, and a tremor that worsens when reaching for something. In long-standing disease, speech may become slurred or develop an uneven, halting rhythm. Pain, while not the dominant feature of most demyelinating conditions, can take the form of burning leg pain, a tight banding sensation around the trunk or a limb, or brief jolting pains.
How Demyelination Is Diagnosed
MRI is the primary tool. Demyelinating lesions show up as bright spots on specific MRI sequences, appearing in the white matter of the brain. In MS, these lesions have a characteristic pattern: they cluster around the fluid-filled ventricles deep in the brain and often extend outward at right angles, a pattern known as Dawson’s fingers. The location and shape of these lesions help distinguish MS from other conditions that can also cause white matter changes, such as migraines or small vessel disease.
A spinal tap (lumbar puncture) can provide additional evidence. The test looks for oligoclonal bands, which are markers of immune activity happening specifically inside the nervous system. These bands are found in roughly 80% to 90% of MS patients overall, with rates exceeding 90% in Nordic countries, the UK, and Canada. The presence of these bands was reintroduced as a formal diagnostic criterion for MS in 2017 because they are such a persistent and reliable indicator of the disease. In children, however, positivity rates are lower, around 40% to 60%.
Nerve conduction studies can help diagnose peripheral demyelination. These tests measure how quickly electrical signals travel along the nerves in your arms and legs, and slowed conduction points directly to myelin damage.
Treatment and the Path to Myelin Repair
Current treatment for most demyelinating diseases focuses on controlling the immune attack. In MS, disease-modifying therapies suppress or redirect the immune system to reduce the frequency and severity of relapses. These treatments can significantly slow disability progression, but they do not repair myelin that has already been lost.
That gap is why remyelination research has become one of the most active areas in neurology. Phase II clinical trials have now provided proof that stimulating myelin repair in people with MS is feasible. The first successful trial of a remyelinating agent was published in 2017, and several more have followed with varying degrees of success. As of mid-2025, multiple trials are actively recruiting or nearing completion, testing a range of compounds for their ability to promote myelin regrowth in different forms of MS and optic neuritis, with results expected between late 2025 and 2027.
The results so far are cautiously encouraging. Early-stage data support that remyelination is achievable in patients, but many trials have not met their primary goals, indicating that the approach still needs refinement. The challenge is partly biological (getting the right cells to rebuild myelin in the right places) and partly about measurement (current tools may not be sensitive enough to detect subtle repair). If these hurdles are cleared, remyelination therapies could eventually complement existing immune treatments by protecting exposed axons and slowing disability in ways that stopping inflammation alone cannot.
For peripheral demyelinating conditions like Guillain-Barré syndrome, the outlook differs. The peripheral nervous system has a stronger natural capacity for remyelination, and many patients recover significant function over weeks to months once the acute immune attack is treated.